217 related articles for article (PubMed ID: 37007066)
1. Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study.
Wang X; Wang T; Chu Y; Liu J; Yi C; Yu X; Wang Y; Zheng T; Cao F; Qu L; Yu B; Liu H; Ding F; Wang S; Wang X; Hao J; Wang X
Front Oncol; 2023; 13():1089234. PubMed ID: 37007066
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Shi Y
J Cancer Res Ther; 2022 Sep; 18(5):1425-1431. PubMed ID: 36204892
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
Ljubicic L; Janzic U; Unk M; Terglav AS; Mohorcic K; Seiwerth F; Bitar L; Badovinac S; Plestina S; Korsic M; Kukulj S; Samarzija M; Jakopovic M
Radiol Oncol; 2023 Sep; 57(3):397-404. PubMed ID: 37665737
[TBL] [Abstract][Full Text] [Related]
9. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y; Wu L; Yu X; Xing P; Wang Y; Zhou J; Wang A; Shi J; Hu Y; Wang Z; An G; Fang Y; Sun S; Zhou C; Wang C; Ye F; Li X; Wang J; Wang M; Liu Y; Zhao Y; Yuan Y; Feng J; Chen Z; Shi J; Sun T; Wu G; Shu Y; Guo Q; Zhang Y; Song Y; Zhang S; Chen Y; Li W; Niu H; Hu W; Wang L; Huang J; Zhang Y; Cheng Y; Wu Z; Peng B; Sun J; Mancao C; Wang Y; Sun L
Cancer Commun (Lond); 2022 Dec; 42(12):1314-1330. PubMed ID: 36336841
[TBL] [Abstract][Full Text] [Related]
11. Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
Yi Y; Liu Z; Fang L; Li J; Liu W; Wang F; Fu P; Xie C; Liu J; Song B
Cancer Chemother Pharmacol; 2020 Jul; 86(1):65-74. PubMed ID: 32533335
[TBL] [Abstract][Full Text] [Related]
12. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Grohé C; Wehler T; Dechow T; Henschke S; Schuette W; Dittrich I; Hammerschmidt S; Müller-Huesmann H; Schumann C; Krüger S; Atz J; Kaiser R
Transl Lung Cancer Res; 2022 Oct; 11(10):2010-2021. PubMed ID: 36386456
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
[TBL] [Abstract][Full Text] [Related]
16. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
Zhang YF; Yu YF; Lu S
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
Moro-Sibilot D; Audigier-Valette C; Merle P; Quoix E; Souquet PJ; Barlesi F; Chouaid C; Molinier O; Bennouna J; Lavolé A; Mazières J; Toffart AC; Langlais A; Morin F; Zalcman G
Lung Cancer; 2015 Aug; 89(2):139-45. PubMed ID: 26059274
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease.
Gao G; Zhou C; Huang Y; Hong Z; Yu P; Chen Y; Gao J; Zhang K; Xie Z; Zhang J; Li S; Masashi N; Qin Y
Transl Lung Cancer Res; 2021 Jun; 10(6):2573-2587. PubMed ID: 34295663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
